File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: MPN-628 Surpass-ET: Ropeginterferon Alfa-2b (P1101) vs Anagrelide as Second Line Therapy in Essential Thrombocythemia

TitleMPN-628 Surpass-ET: Ropeginterferon Alfa-2b (P1101) vs Anagrelide as Second Line Therapy in Essential Thrombocythemia
Authors
Issue Date1-Sep-2023
PublisherElsevier
Citation
Clinical Lymphoma, Myeloma and Leukemia, 2023, v. 23 How to Cite?
Persistent Identifierhttp://hdl.handle.net/10722/340307
ISSN
2023 Impact Factor: 2.7
2023 SCImago Journal Rankings: 0.548

 

DC FieldValueLanguage
dc.contributor.authorMasarova, Lucia-
dc.contributor.authorKomatsu, Norio-
dc.contributor.authorGill, Harinder-
dc.contributor.authorJin, Jie-
dc.contributor.authorLee, Sung-Eun-
dc.contributor.authorHou, Hsin-An-
dc.contributor.authorSato, Toshiaki-
dc.contributor.authorQin, Albert-
dc.contributor.authorUrbanski, Raymond-
dc.contributor.authorShih, Weichung-
dc.contributor.authorZagrijtschuk, Oleh-
dc.contributor.authorZimmerman, Craig-
dc.contributor.authorMesa, Ruben-
dc.date.accessioned2024-03-11T10:43:10Z-
dc.date.available2024-03-11T10:43:10Z-
dc.date.issued2023-09-01-
dc.identifier.citationClinical Lymphoma, Myeloma and Leukemia, 2023, v. 23-
dc.identifier.issn2152-2650-
dc.identifier.urihttp://hdl.handle.net/10722/340307-
dc.languageeng-
dc.publisherElsevier-
dc.relation.ispartofClinical Lymphoma, Myeloma and Leukemia-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.titleMPN-628 Surpass-ET: Ropeginterferon Alfa-2b (P1101) vs Anagrelide as Second Line Therapy in Essential Thrombocythemia-
dc.typeArticle-
dc.identifier.doi10.1016/S2152-2650(23)01261-2-
dc.identifier.volume23-
dc.identifier.issnl2152-2669-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats